Diagnostic performance of plasma biomarkers for detecting amyloid co‐pathology in Neuronal α‐Synuclein Disease

A. Gordon Smith, Sara A. Lorkiewicz, Laia Montoliu‐Gaya, Ted N. Wilson, Nicholas Ashton, Burak Arslan, Melanie J. Plastini, Christina B. Young, Joseph R. Winer, Marian Shahid, Hillary Vossler, Veronica Ramirez, Tianyu Pan, Geoffrey A. Kerchner, Katrin I. Andreasson, Victor W. Henderson, Thomas J. Montine, Lu Tian, Elizabeth C. Mormino, Henrik Zetterberg, Kathleen L. Poston, Carla AbdelnourAlzheimer 2025 · DOI

TL;DR

This study investigates the diagnostic power of plasma biomarkers for detecting amyloid (Aβ) pathology, specifically in individuals who also have alpha-synuclein (αSyn) pathology. The key finding is that plasma pTau217, alone and combined with other biomarkers, shows strong accuracy in identifying Aβ in the presence of αSyn, suggesting its potential for clinical screening and trial stratification in neurodegenerative diseases.

What Problem Does This Paper Address?

Neurodegenerative diseases, such as Alzheimer's disease and Lewy body dementia, often involve the co-occurrence of multiple protein pathologies, including amyloid plaques (Aβ), tau tangles, and alpha-synuclein aggregates (αSyn). This complex interplay contributes to the diverse clinical presentations and disease progression observed in patients. While promising plasma biomarkers have emerged for detecting Aβ, their performance in the context of co-existing αSyn pathology has been less explored. This paper aims to bridge this gap by evaluating the diagnostic accuracy of several plasma biomarkers for Aβ detection in individuals with and without αSyn pathology, a crucial step for developing effective diagnostic tools and targeted therapies.

Methods

The researchers analyzed five plasma biomarkers: pTau181, pTau217, Aβ42/40 ratio, GFAP, and NfL. They used established methods to determine an individual's αSyn status (using the CSF SAAmplify-aSYN test) and Aβ status (using the CSF Aβ42/40 ratio). The study involved a cohort of 180 participants, categorized into four groups based on their Aβ and αSyn status: aSyn-/Aβ- (n=60), aSyn-/Aβ+ (n=53), aSyn+/Aβ- (n=35), and aSyn+/Aβ+ (n=32). Descriptive comparisons of plasma biomarker levels were made across these groups. The core of the analysis involved evaluating the diagnostic accuracy of each plasma biomarker in predicting Aβ status, both in individuals with αSyn (aSyn+) and without αSyn (aSyn-). This was achieved using receiver-operating characteristic (ROC) curve analyses, with comparisons between biomarkers performed using the DeLong test.

Datasets

The study utilized data from a cohort of 180 Stanford research participants. These participants were categorized into four groups based on their amyloid (Aβ) and alpha-synuclein (αSyn) pathology status, as determined by CSF tests. The study did not introduce a new benchmark dataset but rather evaluated existing plasma biomarkers against established CSF markers for Aβ and αSyn.

Key Insights and Ideas

  • The challenge of co-pathology: Understanding how biomarkers perform when multiple proteinopathies are present is critical for accurate diagnosis and effective treatment development.
  • pTau217 shines in the presence of αSyn: The study highlights that plasma pTau217 is particularly effective at detecting amyloid pathology, even when alpha-synuclein pathology is also present. This is a significant finding because many neurodegenerative diseases involve both.
  • Aβ biomarkers are generally affected by αSyn: The study found that plasma pTau181, pTau217, Aβ42/40, and GFAP levels were elevated in individuals with amyloid pathology, irrespective of their αSyn status. This suggests these markers are sensitive to amyloid itself.
  • NfL as a marker of overall neurodegeneration: Plasma NfL levels were highest in the group with both amyloid and alpha-synuclein pathology, hinting at its role as a general marker of neuroaxonal damage in complex neurodegenerative conditions.
  • Potential for clinical application: The strong performance of plasma pTau217 in detecting Aβ in the context of αSyn pathology opens doors for its use in screening and stratifying patients for clinical trials, especially for diseases like Lewy body dementia and Parkinson's disease.

Key Results

  • Plasma pTau181, pTau217, Aβ42/40, and GFAP levels were significantly higher in individuals with amyloid pathology (Aβ+), regardless of their αSyn status.
  • Plasma NfL levels were highest in the group with both αSyn and Aβ pathology (aSyn+/Aβ+).
  • In individuals with αSyn pathology (aSyn+), plasma pTau217 demonstrated the highest diagnostic accuracy for detecting Aβ, with an Area Under the Curve (AUC) of 0.92. Aβ42/40 also showed good performance (AUC = 0.85).
  • In individuals without αSyn pathology (aSyn-), individual biomarker models performed similarly, with pTau217 showing an AUC of 0.83 and Aβ42/40 an AUC of 0.81.
  • Including demographic factors like age, sex, and APOE4 status did not improve the accuracy of detecting Aβ in aSyn+ participants but did enhance the accuracy of plasma NfL for detecting Aβ in aSyn- participants.

Limitations and Future Work

The authors acknowledge that while plasma pTau217 shows promise, further validation in larger and more diverse cohorts is warranted. They also suggest that combining multiple plasma biomarkers might offer even greater diagnostic power. Future work could focus on refining these multi-biomarker panels and exploring their utility in longitudinal studies to track disease progression and treatment response. The study also noted that while age, sex, and APOE4 status didn't improve Aβ detection in aSyn+ individuals, their impact on other biomarkers or disease trajectories might be worth further investigation.

Summary updated

Abstract

Plasma pTau217 (individually and combined with other biomarkers) accurately detects Aβ in αSyn+ participants. These findings highlight potential for using plasma pTau217 as a tool for Aβ screening and stratification in clinical trials for alpha-synucleinopathies such as dementia with Lewy bodies and Parkinson's disease.
BibTeX
@inproceedings{smith2025diagnostic,
  author = {A. Gordon Smith and Sara A. Lorkiewicz and Laia Montoliu‐Gaya and Ted N. Wilson and Nicholas Ashton and Burak Arslan and Melanie J. Plastini and Christina B. Young and Joseph R. Winer and Marian Shahid and Hillary Vossler and Veronica Ramirez and Tianyu Pan and Geoffrey A. Kerchner and Katrin I. Andreasson and Victor W. Henderson and Thomas J. Montine and Lu Tian and Elizabeth C. Mormino and Henrik Zetterberg and Kathleen L. Poston and Carla Abdelnour},
  title = {{Diagnostic performance of plasma biomarkers for detecting amyloid co‐pathology in Neuronal α‐Synuclein Disease}},
  booktitle = {Alzheimer},
  year = {2025},
  doi = {10.1002/alz70856\_104596},
}
Figure